VSTM2L

Across TCGA pan-cancer cohorts, VSTM2L RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of VSTM2L’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where VSTM2L RNA is more highly expressed in tumor relative to normal tissue. In most cancer types VSTM2L is over-expressed in tumor, although a few such as LUSC and READ show the opposite, repressed pattern.

THCA, LUAD, and LUSC are the cancer types where VSTM2L tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in VSTM2L RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	III,IV	+2.334	<.001	9	view →
LUAD	All	III,IV	+1.869	<.001	9	view →
LUSC	Female	All	−2.171	<.001	6	view →
BRCA	Female	All	+1.230	<.001	6	view →
KIRP	All	All	+1.691	.001	3	view →
READ	All	All	−1.086	.004	3	view →
KIRC	Female	All	−0.584	<.001	3	view →
PAAD	All	All	+2.727	.005	2	view →
UCEC	All	All	−2.096	<.001	2	view →
PRAD	All	All	+1.255	<.001	2	view →
STAD	All	IV	−1.310	.018	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

VSTM2L–THCA

Open the THCA breakdown →